Published in
Springer, Targeted Oncology, 1(16), p. 47-57, 2020
DOI: 10.1007/s11523-020-00767-1
Links
Tools
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Journal article published in 2020 by
Céleste Lebbé,
Antoine Italiano,
Nadine Houédé,
Ahmad Awada,
Philippe Aftimos,
Thierry Lesimple,
Monica Dinulescu,
Jan H. M. Schellens,
Suzanne Leijen,
Sylvie Rottey,
Vibeke Kruse,
Richard Kefford 
,
Eric Raymond,
Sandrine Faivre,
Celine Pages
and other authors.
,
Eric Raymond,
Sandrine Faivre,
Celine Pages
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 